|
|
|
|
|
|
Sponsored by: |
University of Wisconsin, Madison |
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00065767 |
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.
Condition | Intervention | Phase |
Alzheimer Disease |
Drug: Raloxifene |
Phase II Phase III |
Genetics Home Reference related topics: | Alzheimer disease |
MedlinePlus related topics: | Alzheimer's Disease Memory |
ChemIDplus related topics: | Raloxifene Raloxifene hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease |
Estimated Enrollment: | 20 |
Study Start Date: | September 2001 |
Estimated Study Completion Date: | December 2004 |
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication (classified as Selective Estrogen Receptor Modulators (SER's)) approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease. Patients who volunteer for this study will need to visit the clinic 7 times (participate) over a period of five months and will receive either raloxifene or a harmless, inactive pill called a placebo. Neither the volunteers nor the study staff will know which type of pill a patient receives. Patients must be generally healthy and have mild-to-moderate dementia. There must be a patient caregiver who can watch for side effects and ensure that the patient takes the study pills on schedule over a period of three months.
Patients will undergo neuropsychological tests and an evaluation of the ability to live independently at each visit as well as laboratory evaluations, such as the taking of blood. Each visit will last approximately 3 hours. A total of 20 patients is being recruited to participate in this study at the University of Wisconsin.
Ages Eligible for Study: | 55 Years to 90 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Wisconsin | |||||
University of Wisconsin Memory Research Program | |||||
Madison, Wisconsin, United States, 53705 |
University of Wisconsin, Madison |
Principal Investigator: | Sanjay Asthana, MD | William S. Middleton VA Hospital, University of Wisconsin Memory Research Program |
University of Wisconsin Memory Research Program 
  |
Study ID Numbers: | IA0049, IRB M1285 |
First Received: | July 31, 2003 |
Last Updated: | March 23, 2006 |
ClinicalTrials.gov Identifier: | NCT00065767 |
Health Authority: | United States: Federal Government |
|
|
|
|
|